Xth Eurasian Hematology-Oncology Congress

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Event

Playback speed

10 seconds

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and 2nd Line IO Treatment Options + TKI Resistance Mechanisms

By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman

206 views

November 12, 2019

Comments 0

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley

The First Treatment Choice Matters

Feat. A. Ip

Lung

Management of ALK+ NSCLC Through First and Subsequent Lines of Thera…

Xth Eurasian Hematology-Oncology Congress

P. Yumuk

89 views

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy…

Xth Eurasian Hematology-Oncology Congress

P. Yumuk

170 views

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Trea…

Xth Eurasian Hematology-Oncology Congress

M. Erman

110 views

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and …

Xth Eurasian Hematology-Oncology Congress

M. Erman

206 views

Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

121 views

1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced NSCL…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

181 views

Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is Treatme…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

288 views